TScan Therapeutics, Inc. (TCRX) Latest Company News

Oct 16, 2026, 20:53 UTC
TScan Therapeutics appointed R. Keith Woods as chairperson of its Nominating and Corporate Governance Committee.
Oct 16, 2026, 20:53 UTC
TScan Therapeutics appointed Stephen Biggar to its Nominating and Corporate Governance Committee.
Oct 16, 2026, 20:53 UTC
Gabriela Gruia, M.D. resigned from TScan Therapeutics' board of directors.
Oct 16, 2026, 20:53 UTC
Garry Nicholson resigned from TScan Therapeutics' board of directors.
Sep 30, 2026, 21:04 UTC
TScan Therapeutics, Inc. disclosed that Chief Financial Officer Jason A. Amello and Chief Medical Officer Chrystal Louis will depart effective November 1, 2026.
Sep 11, 2026, 12:04 UTC
TScan Therapeutics, Inc. granted Chief Legal and Strategy Officer Zoran Zdraveski, JD, Ph.D. 1,050,000 restricted stock units effective September 8, 2026.
Sep 11, 2026, 12:04 UTC
TScan Therapeutics, Inc. granted Chief Executive Officer Gavin MacBeath, Ph.D. 2,400,000 restricted stock units effective September 8, 2026.
Sep 2, 2026, 11:25 UTC
TScan Therapeutics terminated CFO Jason A. Amello and CMO Chrystal Louis, effective September 2, 2026, and CEO Gavin MacBeath assumed the additional role of Chief Financial Officer.
Sep 2, 2026, 11:00 UTC
TScan Therapeutics announced a strategic reorganization to focus on in vivo cell therapy for solid tumors, including a workforce reduction of approximately 75%, and paused further enrollment in the Phase 3 ALLOHA-2 study of TSC-101 due to insufficient capital, extending its runway into Q4 2027.
Source:
- globenewswire.com
- benzinga.com
Aug 12, 2026, 11:00 UTC
TScan Therapeutics shared positive initial data from Cohort C of its Phase 1 ALLOHA study, validating its internal commercial-ready manufacturing process.
Source:
- globenewswire.com
Aug 12, 2026, 11:00 UTC
TScan Therapeutics dosed the first patient in its Phase 3 ALLOHA-2 study, with topline readout expected mid-2028.
Source:
- globenewswire.com
Aug 12, 2026, 11:00 UTC
TScan Therapeutics reported financial results for the second quarter of 2026, with cash and cash equivalents funding operations into the second quarter of 2027.
Source:
- globenewswire.com
- zacks.com
Jun 3, 2026, 13:19 UTC
Cellares and TScan Therapeutics announced an agreement to evaluate automated manufacturing of TSC-101 for patients with hematologic malignancies.
Source:
- businesswire.com

TCRX

TScan Therapeutics appointed R. Keith Woods as chairperson of its Nominating and Corporate Governance Committee.

TScan Therapeutics appointed Stephen Biggar to its Nominating and Corporate Governance Committee.

Gabriela Gruia, M.D. resigned from TScan Therapeutics' board of directors.

Garry Nicholson resigned from TScan Therapeutics' board of directors.

TScan Therapeutics, Inc. disclosed that Chief Financial Officer Jason A. Amello and Chief Medical Officer Chrystal Louis will depart effective November 1, 2026.

TScan Therapeutics, Inc. granted Chief Legal and Strategy Officer Zoran Zdraveski, JD, Ph.D. 1,050,000 restricted stock units effective September 8, 2026.

TScan Therapeutics, Inc. granted Chief Executive Officer Gavin MacBeath, Ph.D. 2,400,000 restricted stock units effective September 8, 2026.

TScan Therapeutics terminated CFO Jason A. Amello and CMO Chrystal Louis, effective September 2, 2026, and CEO Gavin MacBeath assumed the additional role of Chief Financial Officer.

TScan Therapeutics announced a strategic reorganization to focus on in vivo cell therapy for solid tumors, including a workforce reduction of approximately 75%, and paused further enrollment in the Phase 3 ALLOHA-2 study of TSC-101 due to insufficient capital, extending its runway into Q4 2027.

TScan Therapeutics shared positive initial data from Cohort C of its Phase 1 ALLOHA study, validating its internal commercial-ready manufacturing process.

TScan Therapeutics dosed the first patient in its Phase 3 ALLOHA-2 study, with topline readout expected mid-2028.

TScan Therapeutics reported financial results for the second quarter of 2026, with cash and cash equivalents funding operations into the second quarter of 2027.

Cellares and TScan Therapeutics announced an agreement to evaluate automated manufacturing of TSC-101 for patients with hematologic malignancies.